Hikma Pharmaceuticals PLC, a UK-based multinational pharmaceutical company, announced on Tuesday that on the two-year anniversary of its launch, it has now donated more than 375,000 doses of KLOXXADO (naloxone HCl) nasal spray 8mg in the US.

The company says that this is an important milestone in its ongoing work to help combat the opioid overdose epidemic.

According to the company, KLOXXADO contains twice as much naloxone per spray as Narcan(R) (naloxone HCl) 4mg nasal spray, in a ready-to- use format to reverse the effects of opioid overdose. Since launching KLOXXADO in 2021, Hikma has donated the lifesaving medicine to harm reduction groups, community organisations and others across the US. With the help of more than 40 donation partners, KLOXXADO has been distributed for free in places where the company says it can have the biggest impact, including music festivals, downtowns and schools.

Brian Hoffmann, Hikma Generics president, stated: "Since its launch two years ago, KLOXXADO has quickly become an essential tool for those on the front lines working to reverse opioid overdoses and save lives.

"We are working closely with our partners across the country to ensure the more than 375,000 doses of KLOXXADO that have now been donated are reaching those who need it most, including patients, health care providers, first responders, harm reduction groups and others. As the opioid overdose epidemic continues, we are committed to expanding access to KLOXXADO, and all forms of naloxone that Hikma manufactures, to meet the urgent needs of US patients and communities."